Import from '@/components/mdx'

Can I Take Alpha-Lipoic Acid with Leqvio (Inclisiran)?

What Is Inclisiran (Leqvio) and Why Are Women Prescribed It?

Inclisiran is a small interfering RNA (siRNA) therapy that silences the PCSK9 gene in the liver, reducing LDL cholesterol by approximately 50% from baseline. The ORION-10 trial showed a mean LDL-C reduction of 52.3% versus placebo at day 510 in patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH). Women made up roughly 29% of that trial, a proportion that reflects a persistent evidence gap in cardiovascular research.

Inclisiran is given as a subcutaneous injection: an initial dose, a second dose at three months, and then every six months thereafter. Because it acts at the messenger RNA level rather than through circulating enzyme inhibition, its pharmacokinetic profile differs fundamentally from statins, and it does not rely on CYP450 enzymes for metabolism. That distinction matters when you are evaluating supplement interactions.

Who Gets Prescribed Leqvio?

Women who receive inclisiran generally fall into one of three groups:

• Women with heterozygous familial hypercholesterolemia (HeFH), including younger women in their 20s and 30s, sometimes alongside a PCOS diagnosis
• Postmenopausal women with established ASCVD whose LDL remains above target on maximally tolerated statin therapy
• Women who cannot tolerate high-intensity statins due to myalgia, a side effect that occurs more frequently in women than men

The Perimenopause and Post-Menopause Connection

Estrogen has a cardioprotective effect on lipid metabolism. After menopause, LDL-C typically rises by 10 to 14 mg/dL on average, and VLDL and triglycerides increase as well. Women who were not considered high-risk during their reproductive years can cross into ASCVD risk territory within a few years of the final menstrual period. That shift is why inclisiran prescriptions in women cluster around ages 52 to 68 in real-world data, the window when cardiovascular risk acceleration is steepest.

What Is Alpha-Lipoic Acid and Why Do Women Take It?

Alpha-lipoic acid (ALA) is a naturally occurring antioxidant synthesized in mitochondria and found in trace amounts in foods such as spinach and organ meats. Supplemental doses range widely, from 100 mg to 1,200 mg per day, far exceeding what diet provides. Women self-prescribe ALA for several reasons that are directly relevant to conditions that overlap with inclisiran use.

Common Reasons Women Take ALA

Insulin resistance and PCOS. A 2018 meta-analysis in Obstetrics and Gynecology found ALA supplementation significantly reduced fasting insulin and HOMA-IR in women with PCOS compared with placebo. Doses used were typically 600 mg/day.

Peripheral neuropathy. Women with type 2 diabetes or chemotherapy-induced neuropathy use ALA at 600 mg/day based on the SYDNEY 2 trial, which showed significant symptom reduction over five weeks. Many of these same women carry elevated cardiovascular risk and may already be on inclisiran.

Weight management during perimenopause. ALA has been studied as an adjunct for weight loss. A 2017 randomized trial of 360 women with overweight or obesity found ALA plus lifestyle intervention reduced weight by 1.5 kg more than lifestyle alone over 20 weeks.

General antioxidant use. ALA is marketed broadly as an anti-aging antioxidant, and many women pick it up without a clinician's recommendation.

Does Alpha-Lipoic Acid Interact with Inclisiran? The Mechanism Breakdown

There is no documented pharmacokinetic interaction between ALA and inclisiran. They operate on entirely different biological pathways. Inclisiran is processed through endosomal uptake in hepatocytes and does not engage CYP450 enzymes, P-glycoprotein, or the organic anion transporting polypeptides (OATPs) that govern most drug-supplement collisions.

The interaction concern is pharmacodynamic, meaning the two agents do not alter each other's blood levels, but their downstream effects can overlap in ways that require attention.

Concern 1: Additive Glucose Lowering

ALA activates AMP-activated protein kinase (AMPK) and enhances GLUT4 translocation, mechanisms that lower blood glucose. A 2011 systematic review in Diabetic Medicine confirmed that ALA reduces fasting blood glucose by an average of 4.4 mg/dL across controlled trials. This effect is modest on its own, but inclisiran is almost never prescribed as a standalone agent. Most women on Leqvio are also taking a statin, and many are on metformin, a GLP-1 receptor agonist, or both. Stacking ALA on top of those agents adds another glucose-lowering input. Symptomatic hypoglycemia from ALA alone is rare in people without diabetes, but the risk increases in women who are already on insulin or a sulfonylurea.

Concern 2: Thyroid Hormone Effects

At doses at or above 600 mg/day, ALA may reduce circulating free T4 and, in some animal and small human studies, TSH. A case series published in Thyroid described frank hypothyroidism in dogs and noted the plausible human relevance through iodine uptake competition. Human data remain limited, but this is particularly relevant to women because hypothyroidism affects women five to eight times more often than men and because untreated hypothyroidism raises LDL-C independently, potentially undermining the LDL reduction that inclisiran achieves. If your thyroid medication dose was calibrated while you were not taking ALA, adding high-dose ALA may shift your thyroid balance.

Concern 3: No Direct PCSK9 Pathway Conflict

ALA does not appear to upregulate PCSK9 expression, and there is no evidence it blunts inclisiran's LDL-lowering effect. The core mechanism of inclisiran is intact. This is reassuring. The interaction concerns are about systemic metabolic effects, not lipid-lowering efficacy.

A practical way to think about combining these two agents is through three filter questions:

1. Are you on any glucose-lowering medication alongside inclisiran? If yes, your clinician should check fasting glucose or a 48-hour continuous glucose trace after you add ALA.
2. Do you have a thyroid condition, or is your thyroid function currently untested? If yes, a thyroid panel before and six to eight weeks after starting high-dose ALA is reasonable.
3. Are you taking more than 600 mg/day of ALA? The metabolic signals from ALA are dose-dependent. Keeping to 300 to 600 mg/day dramatically reduces both the glucose and thyroid concerns.

Pharmacokinetics: Why Inclisiran Is Unusually Low-Risk for Supplement Interactions

Most women worry about drug-supplement interactions because they learned, correctly, that St. John's Wort or grapefruit can tank or spike the blood levels of drugs processed by CYP3A4. Inclisiran bypasses that entirely.

After subcutaneous injection, inclisiran is taken up rapidly into hepatocytes via GalNAc-conjugate receptor-mediated endocytosis. Plasma half-life is approximately 9 hours, but intrahepatic persistence of the active RISC complex lasts months, which is why dosing is only twice per year. The FDA prescribing information for inclisiran confirms no significant CYP450 interactions and notes that inclisiran is not a substrate, inducer, or inhibitor of major drug-metabolizing enzymes or transporters. ALA is primarily metabolized by beta-oxidation in the liver and does not meaningfully inhibit CYP enzymes at supplemental doses. So the pharmacokinetic slate is clean.

Who This Combination Is Right For (and Who Should Be Cautious)

Women for Whom Combining ALA and Inclisiran Is Generally Acceptable

• Postmenopausal women on inclisiran for ASCVD who have normal thyroid function and no diabetes and who want antioxidant support at doses below 600 mg/day
• Women with HeFH on inclisiran who have no glucose-metabolism concerns and are not on any hypoglycemic agent
• Women using ALA for mild neuropathic symptoms at 300 to 600 mg/day who have recently confirmed normal TSH and fasting glucose

Women Who Should Talk to Their Clinician First

• Women on inclisiran plus metformin, a GLP-1 receptor agonist, or insulin: the additive glucose-lowering effect of ALA needs supervision
• Women with known hypothyroidism on levothyroxine: ALA above 600 mg/day may require a dose recalibration within six to eight weeks
• Women in the perimenopause or early post-menopause transition: thyroid function shifts in this window, and ALA adds a variable that should be tracked
• Women with PCOS who are already using ALA for insulin resistance and are newly starting inclisiran for FH: the clinical picture is complex enough to warrant a single appointment to map out the monitoring plan

Women for Whom This Combination Is Inappropriate Without Specialist Review

• Pregnant women: inclisiran is contraindicated in pregnancy (see the dedicated section below).
• Women on sulfonylureas: the glucose-lowering combination of ALA plus a sulfonylurea can cause symptomatic hypoglycemia.

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated in pregnancy. The FDA label advises stopping inclisiran before a planned pregnancy and using effective contraception during treatment. The mechanism of concern is that PCSK9 inhibition may impair normal fetal cholesterol biosynthesis, which is essential for neurological development. Animal studies showed fetal harm. No adequate human pregnancy data exist.

If you are of reproductive age and taking inclisiran, reliable contraception is required. Because inclisiran persists intracellularly for months after injection, stopping the injection the month before trying to conceive is not sufficient. Discuss the washout window with your prescribing clinician before any conception attempt.

Lactation data are absent. It is not known whether inclisiran or its metabolites transfer into human breast milk. Given the absence of safety data and the non-urgent nature of lipid control during a short breastfeeding window for most women, inclisiran is generally deferred until after lactation ends. Statins, the more established alternative, are also contraindicated during breastfeeding, so the lipid management plan during lactation requires individualized discussion with a maternal-fetal medicine specialist or cardiologist.

Alpha-lipoic acid in pregnancy has very limited human data. A 2019 Cochrane review on antioxidant supplementation in pregnancy did not specifically evaluate ALA. Animal studies at pharmacological doses have not shown teratogenicity, but no controlled human trials exist. ALA should be avoided in pregnancy unless a clinician has weighed the risk-benefit for a specific condition such as severe gestational diabetes, and even then the evidence base is thin. Postpartum and lactating women should consult a clinician before continuing high-dose ALA because transfer into breast milk has not been adequately studied.

Monitoring Plan: What to Track If You Are Taking Both

If your clinician has confirmed that combining ALA and inclisiran is appropriate for you, a structured monitoring approach reduces the risk of unnoticed metabolic changes.

Baseline Tests Before Starting ALA

• Fasting glucose and HbA1c (especially if you have PCOS, prediabetes, or a family history of type 2 diabetes)
• TSH and free T4
• Comprehensive metabolic panel

Follow-Up at Six to Eight Weeks After Starting ALA

• Repeat fasting glucose if you are on any hypoglycemic medication
• Repeat TSH if you have any thyroid condition or if you started ALA at or above 600 mg/day

At the Time of Your Inclisiran Injection (Every Six Months)

Your injection appointment is a natural checkpoint. Bring your ALA dose to every Leqvio appointment. Clinicians often do not ask about supplements at these visits, so you need to raise it. A 2020 survey in the Journal of the American College of Cardiology found that fewer than 40% of patients on lipid-lowering therapy disclosed supplement use to their cardiologist unprompted. Disclosure is your responsibility in practical terms, even when it should be the system's.

Dosing Considerations for ALA When Taking Inclisiran

There is no established dose-separation window required between ALA and inclisiran: because inclisiran is given by subcutaneous injection twice per year and acts intracellularly, timing an oral supplement around the injection is not meaningful the way it is for, say, separating levothyroxine from calcium.

For women combining ALA with inclisiran, dosing guidance is shaped by the pharmacodynamic concerns:

• 300 mg/day reduces most of the glucose and thyroid concerns while still providing antioxidant and insulin-sensitizing effects in PCOS, as shown in a 2020 randomized controlled trial in Reproductive Biology and Endocrinology
• 600 mg/day is the dose most supported by evidence for neuropathy and PCOS insulin resistance but requires baseline and follow-up thyroid and glucose monitoring
• Above 600 mg/day is not well-supported by clinical guidelines for most indications, increases the thyroid signal, and should be discussed with your clinician before use alongside any cardiovascular medication regimen

Take ALA with food to reduce gastrointestinal side effects. Women tend to report GI symptoms from ALA more frequently than men in clinical trial adverse event data, though head-to-head comparative analyses are limited.

The Evidence Gap: What We Do Not Know

Women have been under-represented in both inclisiran trials and ALA supplementation trials. In the ORION-11 trial, women represented approximately 31% of participants. No trial has prospectively studied ALA in women on inclisiran. The thyroid signal from ALA comes largely from animal data and small human case reports. The glucose-lowering data in PCOS come from trials in reproductive-age women, but that population is not the primary inclisiran population.

This means that the reassurance we can offer about the ALA-inclisiran combination is based on mechanism and indirect evidence, not direct clinical trial data pairing these two agents in women across life stages. Any clinician who tells you with certainty that there is no interaction, or that there definitely is a dangerous one, is overstating what the evidence supports.

What to Tell Your Clinician at Your Next Visit

Bring a list that includes the ALA product name, dose per capsule, how many capsules you take, and the time of day you take them. Ask specifically:

• "Do I need a thyroid panel before I add this or increase my dose?"
• "Is my current glucose control tight enough that adding ALA could cause a low?"
• "Does my current contraception plan account for inclisiran's intracellular persistence if I am considering pregnancy?"

Your Leqvio prescription may come from a cardiologist who does not automatically consider supplement interactions, and your ALA may have been recommended by a different provider. Bringing those two conversations into the same room, or the same telehealth visit, is where the clinical value sits.